Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes
Purpose Aspirin and omega-3 fatty acids (FAs) are potential disease modifiers of age-related macular degeneration (AMD), but previous studies have produced inconsistent findings. Randomised evidence for the efficacy and safety of aspirin and omega-3 FAs on AMD is presented in this study.Design ASCEN...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-02-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/2/e090605.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850230639716990976 |
|---|---|
| author | Praveen Patel Rory Collins Richard Peto Mark Davies Sanjiv Banerjee David Simpson John Anderson Louise Bowman Peter Scanlon Amanda Adler Andrew Farmer Helen Cook Laura Evans Elizabeth Williamson Louis Bolter Jane Armitage Peter Sandercock Richard Gray Nilesh Samani Tasso Gazis Richard Haynes Arun Sachdev Eric Wu Elizabeth Wincott Peter Sleight Colin Baigent Marion Mafham Sarah Parish Gavin Brown Susan Hurley Lynne Allsop William Stevens Theingi Aung Allen Young Emily Sammons Georgina Buck Imen Hammami Jill Barton Jonathan Bodansky Roger McPherson Lucy Fletcher Murphy Kevin Ryonfa Lee Sandra Pickworth Monica Willett Michael Lay Ola Murawska Karen Melham Jonathan Latham-Mollart Anna Brewer Mike Olson Jude Kay Alisha Griffiths Helen Clayton Philip Kirby Mike Pennington Dominic Clarke Jenny Anslow Alex Hallam Jenny Witts Sarah Egan Alex Wharton Amy Derbyshire Katherine Hepplestone Sujit Mithra Su Oliver Pauline Wiatrak-Olszewska Kelly Alvey Nick Gregory Priyai Parkinson Prema Maharajan Rachel McFee Donna Sowter John Featonby Richard Furnival Helen Lipinski Hazel Benjamin Tanisha McAfee Emma Payne Payne Liz Still |
| author_facet | Praveen Patel Rory Collins Richard Peto Mark Davies Sanjiv Banerjee David Simpson John Anderson Louise Bowman Peter Scanlon Amanda Adler Andrew Farmer Helen Cook Laura Evans Elizabeth Williamson Louis Bolter Jane Armitage Peter Sandercock Richard Gray Nilesh Samani Tasso Gazis Richard Haynes Arun Sachdev Eric Wu Elizabeth Wincott Peter Sleight Colin Baigent Marion Mafham Sarah Parish Gavin Brown Susan Hurley Lynne Allsop William Stevens Theingi Aung Allen Young Emily Sammons Georgina Buck Imen Hammami Jill Barton Jonathan Bodansky Roger McPherson Lucy Fletcher Murphy Kevin Ryonfa Lee Sandra Pickworth Monica Willett Michael Lay Ola Murawska Karen Melham Jonathan Latham-Mollart Anna Brewer Mike Olson Jude Kay Alisha Griffiths Helen Clayton Philip Kirby Mike Pennington Dominic Clarke Jenny Anslow Alex Hallam Jenny Witts Sarah Egan Alex Wharton Amy Derbyshire Katherine Hepplestone Sujit Mithra Su Oliver Pauline Wiatrak-Olszewska Kelly Alvey Nick Gregory Priyai Parkinson Prema Maharajan Rachel McFee Donna Sowter John Featonby Richard Furnival Helen Lipinski Hazel Benjamin Tanisha McAfee Emma Payne Payne Liz Still |
| collection | DOAJ |
| description | Purpose Aspirin and omega-3 fatty acids (FAs) are potential disease modifiers of age-related macular degeneration (AMD), but previous studies have produced inconsistent findings. Randomised evidence for the efficacy and safety of aspirin and omega-3 FAs on AMD is presented in this study.Design ASCEND-Eye is a substudy of eye effects in the 2×2 factorial design ASCEND (A Study of Cardiovascular Events iN Diabetes) double-blind, randomised, placebo-controlled trial for the primary prevention of cardiovascular events. Reports of AMD diagnoses were sourced from 6 monthly ASCEND follow-up questionnaires and a Visual Function Questionnaire.Participants 15 480 UK adults at least 40 years of age with diabetes but no evident cardiovascular disease.Interventions 100 mg aspirin daily versus placebo and, separately, 1 g omega-3 FAs daily versus placebo.Main outcome measure The first post-randomisation reports of AMD.Results During 7.4 years of follow-up, 122 (1.6%) participants randomised to aspirin were reported as having AMD, compared with 138 (1.8%) randomised to placebo (rate ratio 0.88; 95% CI 0.69 to 1.12; p=0.31). AMD occurred in 130 (1.7%) participants randomised to omega-3 FAs, compared with 130 (1.7%) randomised to placebo (rate ratio 0.99; 95% CI 0.78 to 1.27; p=0.99).Conclusion No clinically-meaningful effects of aspirin or omega-3 FAs on AMD were found. Although the study had very limited statistical power to detect clinically relevant effects, these data overcome some methodological limitations of previous observational studies, providing randomised evidence of both treatments on AMD, which could contribute to future meta-analyses.Trial registration number ISRCTN60635500 and NCT00135226. |
| format | Article |
| id | doaj-art-e41ae65c2e6140e280ded2e512379a9b |
| institution | OA Journals |
| issn | 2044-6055 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-e41ae65c2e6140e280ded2e512379a9b2025-08-20T02:03:47ZengBMJ Publishing GroupBMJ Open2044-60552025-02-0115210.1136/bmjopen-2024-090605Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes Praveen PatelRory CollinsRichard PetoMark DaviesSanjiv BanerjeeDavid SimpsonJohn AndersonLouise Bowman0Peter ScanlonAmanda AdlerAndrew FarmerHelen CookLaura EvansElizabeth WilliamsonLouis BolterJane Armitage1Peter SandercockRichard GrayNilesh SamaniTasso GazisRichard HaynesArun SachdevEric WuElizabeth WincottPeter SleightColin BaigentMarion MafhamSarah Parish2Gavin BrownSusan HurleyLynne AllsopWilliam Stevens3Theingi AungAllen YoungEmily Sammons4Georgina Buck5Imen Hammami6Jill BartonJonathan BodanskyRoger McPhersonLucy FletcherMurphy KevinRyonfa LeeSandra PickworthMonica WillettMichael LayOla MurawskaKaren MelhamJonathan Latham-MollartAnna BrewerMike OlsonJude KayAlisha GriffithsHelen ClaytonPhilip KirbyMike PenningtonDominic ClarkeJenny AnslowAlex HallamJenny WittsSarah EganAlex WhartonAmy DerbyshireKatherine HepplestoneSujit MithraSu OliverPauline Wiatrak-OlszewskaKelly AlveyNick GregoryPriyai ParkinsonPrema MaharajanRachel McFeeDonna SowterJohn FeatonbyRichard FurnivalHelen LipinskiHazel BenjaminTanisha McAfeeEmma Payne PayneLiz StillNuffield Department of Population Health, University of Oxford, Oxford, UKNuffield Department of Population Health, University of Oxford, Oxford, UKNuffield Department of Population Health, University of Oxford, Oxford, UKNuffield Department of Population Health, University of Oxford, Oxford, UKNuffield Department of Population Health, University of Oxford, Oxford, UKNuffield Department of Population Health, University of Oxford, Oxford, UKNuffield Department of Population Health, University of Oxford, Oxford, UKPurpose Aspirin and omega-3 fatty acids (FAs) are potential disease modifiers of age-related macular degeneration (AMD), but previous studies have produced inconsistent findings. Randomised evidence for the efficacy and safety of aspirin and omega-3 FAs on AMD is presented in this study.Design ASCEND-Eye is a substudy of eye effects in the 2×2 factorial design ASCEND (A Study of Cardiovascular Events iN Diabetes) double-blind, randomised, placebo-controlled trial for the primary prevention of cardiovascular events. Reports of AMD diagnoses were sourced from 6 monthly ASCEND follow-up questionnaires and a Visual Function Questionnaire.Participants 15 480 UK adults at least 40 years of age with diabetes but no evident cardiovascular disease.Interventions 100 mg aspirin daily versus placebo and, separately, 1 g omega-3 FAs daily versus placebo.Main outcome measure The first post-randomisation reports of AMD.Results During 7.4 years of follow-up, 122 (1.6%) participants randomised to aspirin were reported as having AMD, compared with 138 (1.8%) randomised to placebo (rate ratio 0.88; 95% CI 0.69 to 1.12; p=0.31). AMD occurred in 130 (1.7%) participants randomised to omega-3 FAs, compared with 130 (1.7%) randomised to placebo (rate ratio 0.99; 95% CI 0.78 to 1.27; p=0.99).Conclusion No clinically-meaningful effects of aspirin or omega-3 FAs on AMD were found. Although the study had very limited statistical power to detect clinically relevant effects, these data overcome some methodological limitations of previous observational studies, providing randomised evidence of both treatments on AMD, which could contribute to future meta-analyses.Trial registration number ISRCTN60635500 and NCT00135226.https://bmjopen.bmj.com/content/15/2/e090605.full |
| spellingShingle | Praveen Patel Rory Collins Richard Peto Mark Davies Sanjiv Banerjee David Simpson John Anderson Louise Bowman Peter Scanlon Amanda Adler Andrew Farmer Helen Cook Laura Evans Elizabeth Williamson Louis Bolter Jane Armitage Peter Sandercock Richard Gray Nilesh Samani Tasso Gazis Richard Haynes Arun Sachdev Eric Wu Elizabeth Wincott Peter Sleight Colin Baigent Marion Mafham Sarah Parish Gavin Brown Susan Hurley Lynne Allsop William Stevens Theingi Aung Allen Young Emily Sammons Georgina Buck Imen Hammami Jill Barton Jonathan Bodansky Roger McPherson Lucy Fletcher Murphy Kevin Ryonfa Lee Sandra Pickworth Monica Willett Michael Lay Ola Murawska Karen Melham Jonathan Latham-Mollart Anna Brewer Mike Olson Jude Kay Alisha Griffiths Helen Clayton Philip Kirby Mike Pennington Dominic Clarke Jenny Anslow Alex Hallam Jenny Witts Sarah Egan Alex Wharton Amy Derbyshire Katherine Hepplestone Sujit Mithra Su Oliver Pauline Wiatrak-Olszewska Kelly Alvey Nick Gregory Priyai Parkinson Prema Maharajan Rachel McFee Donna Sowter John Featonby Richard Furnival Helen Lipinski Hazel Benjamin Tanisha McAfee Emma Payne Payne Liz Still Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes BMJ Open |
| title | Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes |
| title_full | Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes |
| title_fullStr | Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes |
| title_full_unstemmed | Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes |
| title_short | Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes |
| title_sort | effects of aspirin and omega 3 fatty acids on age related macular degeneration in ascend eye a randomised placebo controlled trial in a population with diabetes |
| url | https://bmjopen.bmj.com/content/15/2/e090605.full |
| work_keys_str_mv | AT effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT praveenpatel effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT rorycollins effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT richardpeto effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT markdavies effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT sanjivbanerjee effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT davidsimpson effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT johnanderson effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT louisebowman effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT peterscanlon effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT amandaadler effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT andrewfarmer effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT helencook effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT lauraevans effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT elizabethwilliamson effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT louisbolter effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT janearmitage effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT petersandercock effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT richardgray effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT nileshsamani effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT tassogazis effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT richardhaynes effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT arunsachdev effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT ericwu effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT elizabethwincott effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT petersleight effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT colinbaigent effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT marionmafham effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT sarahparish effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT gavinbrown effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT susanhurley effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT lynneallsop effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT williamstevens effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT theingiaung effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT allenyoung effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT emilysammons effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT georginabuck effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT imenhammami effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT jillbarton effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT jonathanbodansky effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT rogermcpherson effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT lucyfletcher effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT murphykevin effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT ryonfalee effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT sandrapickworth effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT monicawillett effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT michaellay effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT olamurawska effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT karenmelham effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT jonathanlathammollart effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT annabrewer effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT mikeolson effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT judekay effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT alishagriffiths effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT helenclayton effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT philipkirby effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT mikepennington effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT dominicclarke effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT jennyanslow effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT alexhallam effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT jennywitts effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT sarahegan effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT alexwharton effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT amyderbyshire effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT katherinehepplestone effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT sujitmithra effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT suoliver effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT paulinewiatrakolszewska effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT kellyalvey effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT nickgregory effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT priyaiparkinson effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT premamaharajan effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT rachelmcfee effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT donnasowter effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT johnfeatonby effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT richardfurnival effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT helenlipinski effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT hazelbenjamin effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT tanishamcafee effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT emmapaynepayne effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes AT lizstill effectsofaspirinandomega3fattyacidsonagerelatedmaculardegenerationinascendeyearandomisedplacebocontrolledtrialinapopulationwithdiabetes |